Advertisement

Advertisement
Frederick L. Locke, MD, on CAR T-Cell Therapy: Major Milestones

Frederick L. Locke, MD, on CAR T-Cell Therapy: Major Milestones

Analysis of Cause of Death in Patients With Follicular Lymphoma in the Rituximab Era

In a pooled analysis of French and U.S. follicular lymphoma cohorts reported in the Journal of Clinical Oncology, Sarkozy and colleagues found that lymphoma was the most common cause of death during the first decade of the rituximab era in treatment of...

MURANO Trial Follow-up: MRD and Prognosis With Fixed Duration of Venetoclax/Rituximab in Relapsed or Refractory CLL

As reported in the Journal of Clinical Oncology by Kater et al, high undetectable minimal residual disease (MRD) rates persisted after the end of venetoclax (Venclexta)/rituximab (Rituxan) treatment in the phase III MURANO trial in relapsed or refractory ...

Breakthrough Therapy Designation for Brentuximab Vedotin in Front-Line Treatment of Peripheral T-Cell Lymphomas

High Long-Term Risk of Solid Cancers in Survivors of Childhood Hodgkin Lymphoma

A new study may bolster existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. The study showed that certain subgroups of patients have an especially high risk....

Advertisement


Advertisement